Immix Biopharma, Inc. 4

Director-level insider Magda Marquet received 6,250 RSUs and a stock option for 12,500 shares of Immix Biopharma, Inc. common stock at $8.78 per share as equity compensation.

On May 22, 2026, Magda Marquet received an equity compensation package from Immix Biopharma, Inc. consisting of 6,250 restricted stock units of common stock and a stock option to purchase 12,500 shares at an exercise price of $8.78 per share, both granted under the issuer’s 2021 Equity Incentive Plan. The RSUs will vest in full on the earlier of one year from the grant date or the company’s 2027 annual meeting, contingent on her continued service, while the option vests in substantially equal monthly installments over 12 months (or in full at the 2027 annual meeting if that occurs earlier), subject to continued board service. Following these awards, she directly beneficially owns 52,342 shares of common stock (including the RSUs/option context) and is also associated with 20,000 shares held indirectly by Alma Life Sciences, LLC, for which she disclaims beneficial ownership except to the extent of her economic interest.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

4

Source Type

sec

Accession

0001493152-26-026427

Alert Tier

5